Table 3.
Overall analytical performances for saliva compared to nasopharyngeal specimens and by center and prevalence by center.
| All centers | Center 1 | Center 2 | Center 3 | Center 4 | Centers 1 + 3 + 4 |
|
|---|---|---|---|---|---|---|
| Disease prevalence during study | / | 10,1% | 12,5% | 9,1% | 7,4% | / |
| Sensitivity (CI 95%) | 87.8 (83.3–92.3) | 92.2 (85.6–98.8) | 66.7 (51.9–81.5) | 96.8 (90.5–100.0) | 91.5 (85.1–98.0) | 92.8 (88.8–96.7) |
| Specificity (CI 95%) | 97.1 (96.1–98.1) | 97.7 (96.1–99.4) | 97.2 (94.5–99.9) | 94.8 (91.1–98.6) | 97.3 (95.8–98.9) | 97.1 (96.0–98.2) |
| PPV (CI 95%) | 92.3 (88.6–96) | 95.2 (89.8–100.0) | 86.7 (74.5–98.8) | 90.9 (81.1–100.0) | 92.9 (86.8–98.9) | 93.3 (89.5–97.1) |
| NPV (CI 95%) | 97.8 (96.9–98.7) | 99.0 (97.9–100.0) | 91.4 (87.0–95.9) | 99.2 (97.7–100.0) | 98.8 (97.7–99.8) | 98.9 (98.2–99.6) |
| Kappa (CI 95%) | 0.84 (0.80–0.88) | 0.89 (0.83–0.95) | 0.70 (0.56–0.83) | 0.85 (0.76–0.95) | 0.86 (0.80–0.93) | 0.87 (0.83–0.91) |
NP nasopharyngeal; PPV positive predictive value; NPV negative predictive value